A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

SYDNEY, Australia (WKRC) - Researchers believe a possible HIV cure is nearing reality after a "previously impossible discovery." According to The New York Post, citing a results published in the ...

Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in targeting HIV cells. How do you envision gene therapy working with other forms ...

Scientists have found a breakthrough in the search for a cure for HIV, after research uncovered a development “previously thought impossible”. HIV can ‘hide’ itself in white blood cells, meaning the ...